Buprenorphine Extended-Release SC Injection Under Review Again for Opioid Use Disorder
The resubmitted NDA was in response to a Complete Response Letter issued by the FDA in December 2021.
The resubmitted NDA was in response to a Complete Response Letter issued by the FDA in December 2021.
Brightly colored versions of the synthetic opioid fentanyl are appearing across the US, according to the Drug Enforcement Administration (DEA). In a press statement, the Agency reported that the colorful fentanyl, dubbed “rainbow fentanyl”, has been seized in 18 different states and has been found in multiple forms, including pills, powder, and blocks that resemble…
AD04 is a genetically targeted, serotonin-3 receptor antagonist that is believed to reduce alcohol intake by interfering with the dopamine reward system.
The Strategy focuses on 2 main drivers of the opioid epidemic: drug trafficking and untreated addiction.
The FDA defines acute pain as pain, lasting up to 30 days, typically in response to some form of tissue injury, such as trauma or surgery.
LYN-014 is an investigational oral, once-weekly, ultra-long-acting, extended-release levomethadone capsule to treat opioid use disorder.
The consumption of kratom can lead to serious medical outcomes.